89bio to Participate in the Leerink Partners Global Biopharma Conference
05 mars 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
29 févr. 2024 16h05 HE
|
89bio, Inc.
– Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively – – Long-term data from Phase 2b...
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 févr. 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 févr. 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 déc. 2023 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12 déc. 2023 07h30 HE
|
89bio, Inc.
SAN FRANCISCO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
07 déc. 2023 07h00 HE
|
89bio, Inc.
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
06 déc. 2023 16h36 HE
|
89bio, Inc.
SAN FRANCISCO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
04 déc. 2023 07h00 HE
|
89bio, Inc.
—Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology— —Outcomes trial in F4 cirrhotic NASH...
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
27 nov. 2023 08h00 HE
|
89bio, Inc.
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and...